Identification
- Generic Name
- Azapropazone
- DrugBank Accession Number
- DB07402
- Background
Not Available
- Type
- Small Molecule
- Groups
- Withdrawn
- Structure
- Weight
- Average: 298.3397
Monoisotopic: 298.14297584 - Chemical Formula
- C16H18N4O2
- Synonyms
- 1,2-Dihydro-3-dimethylamino-7-methyl-1,2-(propylmalonyl)-1,2,4-benzotriazine
- 3-Dimethylamino-7-methyl-1,2-(n-propylmalonyl)-1,2-dihydro-1,2,4-benzotriazine
- 5-(Dimethylamino)-9-methyl-2-propyl-1H-pyrazolo(1,2-a)(1,2,4)benzotriazine-1,3(2H)-dione
- Apazone
- Azapropazon
- Azapropazona
- Azapropazone
- Azapropazonum
- External IDs
- AHR 3018
- AHR-3018
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Azapropazone may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Abciximab. Acebutolol Azapropazone may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Azapropazone. Acemetacin The risk or severity of adverse effects can be increased when Azapropazone is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Acenocoumarol. Acetaminophen The risk or severity of adverse effects can be increased when Acetaminophen is combined with Azapropazone. Acetohexamide The protein binding of Acetohexamide can be decreased when combined with Azapropazone. Acetylsalicylic acid The therapeutic efficacy of Azapropazone can be decreased when used in combination with Acetylsalicylic acid. Aclidinium Azapropazone may decrease the excretion rate of Aclidinium which could result in a higher serum level. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Rheumox (Amdipharm Mercury Company Limited)
Categories
- ATC Codes
- M01AX04 — Azapropazone
- Drug Categories
- Agents causing hyperkalemia
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antigout Preparations
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Antirheumatic Agents
- Musculo-Skeletal System
- Nephrotoxic agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Triazines
- Uricosuric Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Triazines
- Sub Class
- Aminotriazines
- Direct Parent
- Aminotriazines
- Alternative Parents
- Pyrazolidinones / Benzenoids / 1,3-dicarbonyl compounds / 1,2,4-triazines / Guanidines / Carboxylic acid hydrazides / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organic oxides show 1 more
- Substituents
- 1,2,4-triazine / 1,3-dicarbonyl compound / Amino-1,2,4-triazine / Aminotriazine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxylic acid derivative / Carboxylic acid hydrazide show 12 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- K2VOT966ZI
- CAS number
- 13539-59-8
- InChI Key
- WOIIIUDZSOLAIW-NSHDSACASA-N
- InChI
- InChI=1S/C16H18N4O2/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22/h5,7-9,11H,1,6H2,2-4H3/t11-/m0/s1
- IUPAC Name
- (4S)-7-(dimethylamino)-12-methyl-4-(prop-2-en-1-yl)-2,6,8-triazatricyclo[7.4.0.0^{2,6}]trideca-1(13),7,9,11-tetraene-3,5-dione
- SMILES
- [H][C@@]1(CC=C)C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C
References
- Synthesis Reference
Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG.
- General References
- Not Available
- External Links
- KEGG Drug
- D02966
- PubChem Compound
- 46937068
- PubChem Substance
- 99443873
- ChemSpider
- 25056860
- 1029
- ChEBI
- 38010
- ZINC
- ZINC000033821211
- PDBe Ligand
- AZQ
- Wikipedia
- Azapropazone
- PDB Entries
- 2bx8 / 2bxi / 2bxk
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 187 Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG. - Predicted Properties
Property Value Source Water Solubility 0.641 mg/mL ALOGPS logP 0.92 ALOGPS logP 2.16 ChemAxon logS -2.7 ALOGPS pKa (Strongest Acidic) 5.5 ChemAxon pKa (Strongest Basic) 4.32 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 56.22 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 85.69 m3·mol-1 ChemAxon Polarizability 31.94 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9389 Caco-2 permeable + 0.5728 P-glycoprotein substrate Non-substrate 0.5961 P-glycoprotein inhibitor I Inhibitor 0.8281 P-glycoprotein inhibitor II Inhibitor 0.6484 Renal organic cation transporter Non-inhibitor 0.7843 CYP450 2C9 substrate Non-substrate 0.8218 CYP450 2D6 substrate Non-substrate 0.8107 CYP450 3A4 substrate Substrate 0.6289 CYP450 1A2 substrate Inhibitor 0.5528 CYP450 2C9 inhibitor Non-inhibitor 0.8735 CYP450 2D6 inhibitor Non-inhibitor 0.9188 CYP450 2C19 inhibitor Non-inhibitor 0.8614 CYP450 3A4 inhibitor Non-inhibitor 0.8273 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.725 Ames test AMES toxic 0.5466 Carcinogenicity Non-carcinogens 0.8321 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.4784 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7311 hERG inhibition (predictor II) Non-inhibitor 0.8171
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Carriers
1. DetailsSerum albumin
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:21 / Updated at June 12, 2020 17:42